Ruth Pettengell

5PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 18, 2022
Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.

Elizabeth H Phillips, Catherine Burton, Amy A Kirkwood

|Nov 23, 2021
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.

Christopher P Fox, Matthew J Ahearne, Ruth Pettengell

|Nov 11, 2021
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.

Stephen Booth, Helen M Curley, Csilla Varnai

|Sep 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

Matthew S Davids, Owen A O'Connor, Wojciech Jurczak

|Jan 16, 2021
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.

R Pettengell, R Uddin, A Boumendil

Pageof 1

Frequent Collaborators

1 joint publications

P Dreger

1 joint publications

Wojciech Jurczak

1 joint publications

Pier Luigi Zinzani

1 joint publications

Manish R Patel